Amiodarone: meta-analysis of COVID-19 studies

0 0.5 1 1.5+ All studies -103% 1 143 Improvement, Studies, Patients Relative Risk Mortality -103% 1 143 Ventilation -52% 1 143 RCTs -103% 1 143 Late -103% 1 143 Amiodarone for COVID-19 c19early.org December 2025 Favorsamiodarone Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ RECOVERY-SIRIO Navarese (RCT) -103% 2.03 [0.53-7.80] death 6/71 3/72 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.31 Late treatment -103% 2.03 [0.53-7.80] 6/71 3/72 103% higher risk All studies -103% 2.03 [0.53-7.80] 6/71 3/72 103% higher risk 1 amiodarone COVID-19 study c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.31 Effect extraction pre-specified(most serious outcome) Favors amiodarone Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ RECOVERY-SIRIO Navarese (RCT) -103% 2.03 [0.53-7.80] 6/71 3/72 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.31 Late treatment -103% 2.03 [0.53-7.80] 6/71 3/72 103% higher risk All studies -103% 2.03 [0.53-7.80] 6/71 3/72 103% higher risk 1 amiodarone COVID-19 mortality result c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.31 Favors amiodarone Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ RECOVERY-SIRIO Navarese (RCT) -52% 1.52 [0.57-4.05] 9/71 6/72 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.41 Late treatment -52% 1.52 [0.57-4.05] 9/71 6/72 52% higher risk All studies -52% 1.52 [0.57-4.05] 9/71 6/72 52% higher risk 1 amiodarone COVID-19 mechanical ventilation result c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.41 Favors amiodarone Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ RECOVERY-SIRIO Navarese (RCT) -103% 2.03 [0.53-7.80] death 6/71 3/72 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.31 Late treatment -103% 2.03 [0.53-7.80] 6/71 3/72 103% higher risk All studies -103% 2.03 [0.53-7.80] 6/71 3/72 103% higher risk 1 amiodarone COVID-19 serious outcome c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.31 Effect extraction pre-specified(most serious outcome) Favors amiodarone Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ RECOVERY-SIRIO Navarese (RCT) -30% 1.30 [0.88-1.92] no recov. 71 (n) 72 (n) Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.19 Late treatment -30% 1.30 [0.88-1.92] 71 (n) 72 (n) 30% higher risk All studies -30% 1.30 [0.88-1.92] 71 (n) 72 (n) 30% higher risk 1 amiodarone COVID-19 recovery result c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.19 Favors amiodarone Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ RECOVERY-SIRIO Navarese (RCT) -103% 2.03 [0.53-7.80] death 6/71 3/72 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.31 Late treatment -103% 2.03 [0.53-7.80] 6/71 3/72 103% higher risk All studies -103% 2.03 [0.53-7.80] 6/71 3/72 103% higher risk 1 amiodarone COVID-19 Randomized Controlled Trial c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.31 Effect extraction pre-specified(most serious outcome) Favors amiodarone Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ RECOVERY-SIRIO Navarese (RCT) -103% 2.03 [0.53-7.80] 6/71 3/72 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.31 Late treatment -103% 2.03 [0.53-7.80] 6/71 3/72 103% higher risk All studies -103% 2.03 [0.53-7.80] 6/71 3/72 103% higher risk 1 amiodarone COVID-19 RCT mortality result c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.31 Favors amiodarone Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ RECOVERY-SIRIO Navarese (RCT) -103% 2.03 [0.53-7.80] death 6/71 3/72 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.31 Late treatment -103% 2.03 [0.53-7.80] 6/71 3/72 103% higher risk All studies -103% 2.03 [0.53-7.80] 6/71 3/72 103% higher risk 1 amiodarone COVID-19 peer reviewed studies c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.31 Effect extraction pre-specified(most serious outcome) Favors amiodarone Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ RECOVERY-SIRIO Navarese (RCT) -103% 2.03 [0.53-7.80] death 6/71 3/72 Improvement, RR [CI] Treatment Control RECOVERY-SIRIO Navarese (RCT) -52% 1.52 [0.57-4.05] ventilation 9/71 6/72 RECOVERY-SIRIO Navarese (RCT) -30% 1.30 [0.88-1.92] no recov. 71 (n) 72 (n) Amiodarone COVID-19 outcomes c19early.org December 2025 Favors amiodarone Favors control